A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis Suppurativa

Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin 17A, to which it binds with high affinity. This study investigates izokibep in participants with active Hidradenitis Suppurativa (HS), including tumor necrosis factor-alpha inhibitor (TNFi) naïve participants, and those who had an inadequate response or intolerance to TNFi, or for whom TNFi is contraindicated.

开始日期2023-06-22

申办/合作机构

ACELYRIN, Inc.

NCT05623345

/ Terminated临床2/3期

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Active Psoriatic Arthritis

Izokibep is a potent and selective inhibitor of interleukin (IL)-17A that is being developed for treatment of psoriatic arthritis (PsA).
This study will evaluate the efficacy of izokibep in subjects with PsA.

开始日期2022-11-21

申办/合作机构

ACELYRIN, Inc.

NCT05384249

/ Terminated临床2期

A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Non-infectious, Intermediate-, Posterior- or Pan-uveitis

Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin-17A, to which it binds with high affinity. This study investigates izokibep in subjects with active non-infectious, intermediate-, posterior- or pan-uveitis requiring high-dose steroids.

开始日期2022-08-23

申办/合作机构

ACELYRIN, Inc.

100 项与 Izokibep 相关的临床结果

登录后查看更多信息

100 项与 Izokibep 相关的转化医学

登录后查看更多信息

100 项与 Izokibep 相关的专利（医药）

登录后查看更多信息

项与 Izokibep 相关的文献（医药）

2026-08-03·EXPERT OPINION ON INVESTIGATIONAL DRUGS

Investigational IL-17A antagonist in the treatment of psoriatic arthritis - a review

Review

作者: Nkeck, Jan René ; Osunbor, Osariemen ; Adebajo, Adewale O.

INTRODUCTION:

The global burden of psoriatic arthritis (PsA) is considerable, with major effects on both quality of life and life expectancy. Despite the existence of a diverse array of therapeutic interventions, approximately 40-50% of patients do not achieve the established therapeutic targets. Challenges related to tolerance, compliance, and therapeutic escape persist.

AREAS COVERED:

This study is a comprehensive review of the current literature analyzing the central role of interleukin-17 (IL-17) in the pathogenesis of PsA and emphasizing current and investigational therapies for IL-17A blockade. A structured search was conducted in PubMed for the following terms investigational IL-17A antagonist and Psoriatic arthritis. We aimed for at least 100 research papers published within the last 20 years. In addition, clinical trials databases focusing on phase II - III IL-17A antagonists treatment in Psoriatic Arthritis were also reviewed.

EXPERT OPINION:

The current stage of development and expansion of IL-17A antagonists encompasses the third generation of such molecules. This generation includes small, injectable molecules such as sonelokimab and izokibep; oral molecules; and bispecific monoclonal antibodies. This approach is purported to facilitate enhanced tissue diffusion, augmented efficacy in refractory forms, and simplified utilization. The future of PsA treatments is contingent upon the implementation of precision medicine, which leverages predictive biomarkers to personalize treatment from the moment of diagnosis. This could help control disease early and prevent progression, beyond the current Treat-to-Target strategy which mainly focuses on managing existing symptoms. The overarching objective is no longer to treat to target, but rather to treat to intercept, while ensuring the highest rate of control and tolerance for the patient.

2026-03-01·Mediterranean journal of rheumatology

The Pathophysiological Significance of Dual Inhibition of IL-17A and IL-17F in Psoriatic Arthritis and Axial Spondyloarthritis

Review

作者: Lainis, Vasileios ; Vlachoyiannopoulos, Panayiotis G ; Goules, Andreas V ; Katsouli, Olga

Objective:

Spondylarthritides (SpA), including psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are immune-mediated diseases in which the IL-23/IL-17 axis plays a central role. IL-17A inhibition is already a well-established and effective treatment strategy. Emerging evidence suggests that IL-17F, a cytokine closely related to IL-17A but less potent, is not a passive bystander but a key participant in chronic sustained inflammation and therapeutic escape, offering a compelling concept for dual inhibition. This review aims to examine the pathophysiological significance of dual inhibition of IL-17A and IL-17F in psoriatic arthritis and axial spondyloarthritis.

Methods:

Conducting a search through PubMed/MEDLINE, Scopus, and Web of Science, using keywords and Medical Subject Headings (MeSH) terms such as "spondyloarthritis", "psoriatic arthritis", "IL-17A", "IL-17F", "IL-23", "IL-23 independent mechanisms", "dual inhibition", "pathogenesis", "gut-joint axis", "secukinumab", "ixekizumab", "bimekizumab", "sonelokimab", we select the relevant literature for this comprehensive pathophysiological narrative.

Results:

This review examines the distinct and synergistic functions of IL-17A and IL-17F in key tissues, including the synovium, enthesis, skin, gut, and eye, and their contribution to the paradoxical imbalance of bone remodelling. The advent of dual IL-17A/F inhibitors, particularly bimekizumab has revolutionised our therapeutic approach, offering a promising option for patients with difficult-to-treat SpA. We also discuss emerging technology agents, such as sonelokimab and izokibep.

Conclusion:

Inhibiting both IL-17A and IL-17F signifies not only a significant therapeutic advancement but also a vital strategy towards overcoming the limitations of our current armamentarium in achieving deeper and more sustained remission in SpA. Future studies and long-term data will be essential in determining the position of dual IL-17A/F inhibitors within treatment guidelines.

2025-06-01·ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Article

作者: Wiens, Brian ; Brandt-Juergens, Jan ; Feldwisch, Joachim ; Dokoupilova, Eva ; Drescher, Edit ; Mpofu, Shephard ; Brun, Nikolai C ; Abdel-Kader Martin, Nadia ; Mease, Philip J ; Behrens, Frank ; Ohlman, Sven ; Taylor, Peter C ; Koskinen, Lisa Osterling ; Wetzel, Dieter ; de Vlam, Kurt ; Rowińska-Osuch, Anna ; Stevens, Anne M ; Frejd, Fredrik Y

OBJECTIVES:

To evaluate the efficacy and safety of izokibep, a small protein therapeutic designed to inhibit interleukin-17A, in patients with active psoriatic arthritis (PsA) over 46 weeks.

METHODS:

This phase 2, multicentre, placebo-controlled study randomised adult patients with active PsA 1:1:1 to izokibep 40 mg, izokibep 80 mg, or placebo every 2 weeks for 16 weeks; subsequently, placebo-treated patients switched to izokibep 80 mg. The primary end point was American College of Rheumatology criteria 50 (ACR50) at week 16 for izokibep 80 mg vs placebo. Additional efficacy end points and treatment-emergent adverse events were evaluated through week 16 (placebo-controlled) and week 46.

RESULTS:

Of 172 patients screened, 135 were randomised to izokibep 40 mg (n = 44), izokibep 80 mg (n = 47), or placebo (n = 44). ACR50 response rates were significantly higher for izokibep 80 mg vs placebo at week 16 (52% vs 13%; 2-sided P = .0006) and week 12 (50% vs 6%; P < .0001); lower rates were observed for izokibep 40 mg (48% and 43% for weeks 16 and 12, respectively). Additional analyses of arthritis, psoriasis, enthesitis, dactylitis, and quality of life outcomes supported the efficacy of izokibep at both doses. Response rates generally continued to increase through week 46 with izokibep 80 mg. Treatment-emergent adverse event rates were generally similar across treatment groups except for injection site reactions.

CONCLUSIONS:

Izokibep resulted in significant and clinically meaningful improvements over placebo across multiple disease domains, and the originally randomised 80-mg dose showed continued improvements to week 46. There were no unexpected safety risks identified. Izokibep's small size and high potency have the potential for further improved disease control, justifying additional investigation of higher doses.

178

项与 Izokibep 相关的新闻（医药）

2026-11-07

·风免同行

破局强直性脊柱炎治疗短板！Izokibep凭借独有原理解决传统治疗问题！！

点击蓝字，关注我们国家安全教育日这两天有不少强友在小编后台反映说，自己打了一段时间的生物制剂后，腰背痛轻了，但核磁上的骨髓水肿就是“赖着不走”，可以说非常的头疼。强直性脊柱炎治疗上，疼痛缓解和影像学缓解之间，常常隔着一段让人焦虑的距离。问题到底出在哪儿？近两年被反复讨论的Izokibep，或许能够有效回答这个问题不一样的组织渗透逻辑不少强友被Izokibep的名字带偏，以为它和口服小分子是一回事。实际上Izokibep是一款亲和体分子药物，分子量约18.6 kDa，大概只有传统IL-17单抗的十分之一。可善挺（司库奇尤单抗）、拓咨（依奇珠单抗）这类单抗体积大，能够在血液里待很久，但进入骶髂关节这类血供这些相对“偏远”、结构致密的深层组织时，效果就会比较差了。 Izokibep则采用独有的治疗思路，用更小的尺寸换取更强的组织穿透潜力，同时通过对IL-17A的高亲和力（KD约0.3 pM）来弥补小分子可能“抓不牢”的短板。理论上，它能够解决不少传统生物制剂无法有效控制的问题。 Ⅱ期数据验证治疗思路 Izokibep在银屑病关节炎的Ⅱ期试验中，使用Izokibep 80 mg治疗的银屑病关节炎患者用药16周时有52%的患者成功实现ACR50（症状改善50%以上）远远高于使用安慰剂治疗的患者；附着点炎完全缓解率在80 mg组达到88%。试验随访中，受试者的BASDAI疾病活动评分出现明显下降，中轴关节的活动性炎症得到有效控制，是很好的传统大分子单抗药物渗透不足的短板。这些临床数据很好地说明了小尺寸亲和体的组织渗透设计，在临床终点上是有着确切的效果的。出色的安全性 Ⅱ期汇总数据中，Izokibep在临床当中整体耐受性与现有IL-17抑制剂接近，并未因分子设计的改变而导致出现新的不良反应。出现的念珠菌感染多为轻度、一过性，并未出现炎症性肠病风险信号明显升高的情况。但安全性数据来自样本量有限的Ⅱ期研究，长期的疗效与安全性依旧需要患者更多，时间更久的临床来进行验证更关键的是，评价一款IL-17靶向药对中轴病灶是否“真正到位”，不能只看BASDAI下降，必须看骶髂关节MRI骨髓水肿的消退幅度和结构损伤进展。小结 Izokibep的亲和体设计，在理论上为中轴深层炎症的“渗透难题”提供了一个有科学依据的新解法，银屑病关节炎数据也初步验证了这条路走得通。但它尚未获批，因此目前对于强友来说，它是一个值得保持关注的“候选者”，不是可以立刻替换方案的“答案”。目前有相关生物制剂的临床正在招募强直性脊柱炎患者，入组成功后，可安排就近的三甲医院免费用药一年，入组前全面体检以及入组用药不收取任何费用，名额有限，感兴趣的可以点击下方图片进行报名（报名后注意北京地区来电）参考文献 [1] Kolbinger F, et al. Izokibep: Preclinical development and first-in-human study of a novel IL‑17A neutralizing Affibody molecule in patients with plaque psoriasis [J]. mAbs, 2023,15 (1):2209920. [2] Mease P, et al. Efficacy and Safety of Izokibep, a Novel IL‑17A Inhibitor, in Patients with Active Psoriatic Arthritis: Week 52 Results from a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2b/3 Study [J]. ACR Abstract,2023. [3] 中华医学会风湿病学分会。强直性脊柱炎诊疗指南 (2022 版)[J]. 中华内科杂志，2022,61 (9):961-968. [4] 中华医学会风湿病学分会。强直性脊柱炎 / 脊柱关节炎患者实践指南 [J]. 中华内科杂志，2020,59 (7):513-520. [5] Warrington K, et al. Exploring the Cutting Edge: A Recap of EULAR & ACR 2023 Highlights for Spondyloarthritis, including Psoriatic Arthritis [J]. RMD Open,2024,10 (Suppl1):A124. 本文仅做参考，不构成对任何药物或诊疗方案的推荐、推广或宣传，也不可替代专业医疗建议。如有问题，请咨询医疗卫生专业人士。材料图片等源自网络，侵删

临床2期临床失败

2026-10-03

·雨泽强直新知

新型 IL-17 靶向药来袭！Izokibep 凭渗透优势突破强直治疗短板

引言明明一直在规律打IL-17生物制剂，腰背疼痛缓解了不少，但复查核磁，骶髂关节深处的炎症、骨髓水肿总是消得不够彻底。很多人疑惑，是不是现有药物对深层病灶的作用本身就有局限？其实近两年备受关注的新药Izokibep，刚好能解答这个疑问。依托最新出炉的II期临床数据，我们来看看这款新型IL-17靶向药有什么优势？一、Izokibep并非小分子，而是新型亲和体分子药物（图片来源于网络）很多病友第一眼看到这款药物，很容易被名字误导。首先要纠正一个普遍的认知误区：Izokibep常被称作小分子类靶向药，但它并不是大家理解的口服化学小分子，而是一款全新的亲和体分子药物。这也是它和司库奇尤单抗、依奇珠单抗这类传统IL-17单抗药物最大的区别。二、核心突破：超强组织渗透，解决深层炎症残留难题（图片来源于网络）而Izokibep凭借更小的分子结构，拥有了得天独厚的组织穿透能力。从已公开的II期临床试验数据能直观看到，药物进入人体后，能更快渗透到病灶深层组织，精准作用于炎症靶点，持续压制IL-17介导的炎性反应。试验随访中，受试者的BASDAI疾病活动评分出现明显下降，中轴关节的活动性炎症得到有效控制，弥补了传统大分子单抗药物渗透不足的短板。三、安全性表现：II期数据良好，整体风险可控（图片来源于网络）安全性方面，目前II期试验披露的整体数据相对乐观，整体不良反应和现有IL-17抑制剂相差不大。临床重点关注的念珠菌感染、肠道炎症风险，暂无明显异常数据。不过客观来说，现阶段仅完成II期研究，样本量有限，药物的长期安全性、远期疗效稳定性，还需要后续III期临床试验进一步验证。小结这里也想跟大家说，即便这款药物优势很突出，目前也无法替代市面上成熟的IL-17制剂。一方面它还未正式获批上市，不能用于常规临床治疗；另一方面，II期数据仅能验证初步疗效，针对骨髓水肿逆转、关节结构性损伤保护等关键问题，还需要更多影像数据支撑。关注雨泽强直新知，更多药物资讯、科普干货，我们下期再见~ 目前强直新药正在招募患者，入组成功后，可安排就近的三甲医院免费用药一年，入组前全面体检以及入组用药不收取任何费用，名额有限，关注私即可报名！【私】点击下方公众号名片进入主页即可报名！也可以点击右侧快速报名→→→【快速报名入口】参考文献 [1] Kolbinger F, et al. Izokibep: Preclinical development and first-in-human study of a novel IL‑17A neutralizing Affibody molecule in patients with plaque psoriasis [J]. mAbs, 2023,15 (1):2209920. [2] Mease P, et al. Efficacy and Safety of Izokibep, a Novel IL‑17A Inhibitor, in Patients with Active Psoriatic Arthritis: Week 52 Results from a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2b/3 Study [J]. ACR Abstract,2023. [3] 中华医学会风湿病学分会。强直性脊柱炎诊疗指南 (2022 版)[J]. 中华内科杂志，2022,61 (9):961-968. [4] 中华医学会风湿病学分会。强直性脊柱炎 / 脊柱关节炎患者实践指南 [J]. 中华内科杂志，2020,59 (7):513-520. [5] Warrington K, et al. Exploring the Cutting Edge: A Recap of EULAR & ACR 2023 Highlights for Spondyloarthritis, including Psoriatic Arthritis [J]. RMD Open,2024,10 (Suppl1):A124. 本文仅做参考，不构成对任何药物或诊疗方案的推荐、推广或宣传，也不可替代专业医疗建议。如有问题，请咨询医疗卫生专业人士。材料图片等源自网络，侵删

2026-08-25

·自免医时空

医学前沿｜夫那奇珠单抗成功治疗青少年化脓性汗腺炎：一项病例报告与文献回顾

前言化脓性汗腺炎（HS，又称反常性痤疮）是一种慢性、复发性、致残性毛囊闭锁相关炎症性皮肤病，临床常表现为疼痛性深部结节、脓肿、窦道及瘢痕形成，严重损害患者生活质量。该病临床极易误诊，传统抗生素、局部治疗、免疫抑制剂等方案对中重度HS患者疗效有限。近年来IL‑17炎症通路被证实是HS发病的关键环节，IL‑17抑制剂成为中重度HS重要治疗选择之一。近日，贵州中医药大学第一附属医院唐挺团队于《Frontiers in Immunology》（IF:7.0）发表病例报告与文献回顾[1]，首次报道国产IL‑17A抑制剂夫那奇珠单抗用于青少年中重度化脓性汗腺炎，获得显著且持久的临床疗效，为HS临床治疗增添新证据。研究结果发表于Frontiers in Immunology 一、病例概况 17岁男性青少年，5年反复臀部疼痛结节脓肿，长期误诊。 1 基线信息患者为17岁男性，臀部反复疼痛性结节、脓肿5年，近1周症状加重于2025年3月就诊。自12岁起患者每年无明显诱因发作3‑5次，近半年发作＞2次；既往反复被误诊为疖病、痈、臀部细菌性感染，反复口服阿莫西林、外用夫西地酸乳膏，仅可短暂缓解，病情持续进展，逐步形成窦道、瘢痕。既往体健，无吸烟史，无化脓性汗腺炎家族史，BMI：22.8 kg/m2。 2 皮肤科查体臀部广泛棕黑样色素沉着、散在色素减退、瘢痕形成，多发触痛性皮下结节；右侧臀部可见约1.5 cm×3.5 cm破溃脓肿，伴脓性分泌物、窦道形成，局部波动感、皮温轻度升高。 3 辅助检查创面培养检出少量路邓葡萄球菌；臀部软组织超声提示脓肿形成；血常规、肝肾功能、胸片、结核菌素试验均未见异常。 4 诊断依据2024版化脓性汗腺炎S2k简化版指南[2]：患者具备典型发病部位、典型皮损（结节、脓肿、窦道）、半年内≥2次复发，确诊化脓性汗腺炎（Hurley Ⅱ期）。 5 基线评分疼痛NRS评分：7分；皮肤病生活质量指数（DLQI）：18分；国际化脓性汗腺炎严重度评分（IHS4）：11分；化脓性汗腺炎医师总体评估评分（HS‑PGA）：3分，疾病严重，显著影响患者学习与日常生活。二、治疗方案夫那奇珠单抗240 mg皮下注射，第0、2、4周给药；之后每4周240 mg维持治疗，8周活动性炎症皮损（结节/脓肿/窦道）清除，仅残留色素与瘢痕。结合创面培养提示路邓葡萄球菌继发感染，先给予患者头孢唑林钠1.0g每日3次静脉输注，同时行脓肿切开引流、创面局部护理。充分告知监护人，签署超说明书用药知情同意书后启动夫那奇珠单抗治疗。 1 给药方案夫那奇珠单抗240 mg皮下注射，第0、2、4周给药；之后每4周240 mg维持治疗。 2 疗效随访结果第2周：疼痛显著下降，结节变软、缩小；第4周：疼痛结节进一步缩小，窦道接近愈合；第8周：全部疼痛结节、窦道完全消退，仅遗留色素沉着及少量瘢痕；IHS4由11分降至0分，达到HiSCR100完全应答。首次给药后6个月病情持续稳定，调整方案为每4周交替使用120 mg/240 mg维持。末次随访（治疗启动后10个月）：无新发皮损，生活质量显著改善，无白介素17（IL‑17）抑制剂常见不良反应（口腔念珠菌病、上呼吸道感染等），血常规、肝肾功能监测全程正常。表1. 治疗前后评分变化图1. （A）基线可见臀部广泛色素沉着、瘢痕、破溃脓肿及窦道；（B）夫那奇珠单抗治疗8周后结节脓肿窦道全部消退，仅残留色素及少量瘢痕三、关键讨论发病机制、诊疗难点、药物经济学、IL‑17抑制剂证据梳理 1 IL‑17通路在化脓性汗腺炎发病中的核心作用 HS皮损中IL‑17A基因表达可上调30‑149倍，甚至患者非皮损皮肤IL‑17A基因表达也显著升高。IL‑17A激活角质形成细胞，大量释放S100A8/A9、β‑防御素‑2、趋化因子，招募中性粒细胞、巨噬细胞、淋巴细胞浸润；同时促进巨噬细胞分泌TGF‑β、IL‑1β、IL‑6、TNF‑α，进一步放大炎症，驱动成纤维细胞产生基质金属蛋白酶，促进囊壁破坏、窦道形成，形成“炎症加重‑组织损伤‑细胞因子上调”恶性循环，持续IL‑17信号激活是HS炎症级联反应关键环节，这为IL‑17抑制剂用于HS治疗提供坚实理论基础。 2 HS临床高度误诊，需做好鉴别诊断 HS常被误诊为细菌性毛囊炎、复发性疖病、痈；还需与藏毛窦、聚合性痤疮、肛周克罗恩病、坏疽性脓皮病仔细鉴别：毛囊炎、疖痈：仅浅表毛囊受累，不会出现互通深部窦道、愈合后瘢痕；藏毛窦：病变多局限骶尾部中线，存在毛发嵌入；聚合性痤疮：主要累及面胸背皮脂腺丰富区域；肛周克罗恩病：多伴随腹痛、腹泻、体重下降等消化道症状；坏疽性脓皮病：表现为潜行性紫绀边缘溃疡，存在皮肤高反应性（Pathergy）。临床提示：皮肤褶皱部位反复疼痛结节、脓肿、窦道，一定要提高HS的怀疑，避免反复单用抗生素延误治疗。 3 药物经济学视角：国产生物制剂带来可及性优势本病例治疗决策充分考量药物经济学： 2025年3月启动治疗时，司库奇尤单抗国内虽已获批HS适应症，但尚未进入医保；同年9月纳入医保也仅限成人人群。夫那奇珠单抗国内目前仅获批成人银屑病、强直性脊柱炎，HS应用属于超说明书用药，同样需要全自费，但年度自付费用更低。在疗效、安全性预期相当前提下，结合患者实际情况选择成本效益更优的药物，有助于提升慢性病患者治疗依从性与长期获益，国产IL‑17抑制剂为HS提供高可及性新选择。 4 IL‑17抑制剂治疗HS现有临床证据概览近5年，IL‑17抑制剂在HS的证据从病例报告、开放标签研究推进到大样本随机对照研究：司库奇尤单抗Ⅲ期随机对照试验（RCT）证实每2周给药方案HiSCR应答显著优于安慰剂，疗效维持52周[3]；双靶点IL‑17A/F抑制剂比奇珠单抗Ⅱ、Ⅲ期研究显示良好应答，2年持续高缓解率[4-5]； CJM112、Izokibep、Sonelokimab等IL‑17抑制剂也已完成初步临床探索[6-8]。以上证据共同支持IL‑17通路抑制剂是中重度HS重要治疗方案，国产夫那奇珠单抗基于同样作用机制，有望为国内HS患者提供兼顾疗效、安全性与可负担性的治疗新选项。总结本病例首次报道国产IL‑17A抑制剂夫那奇珠单抗成功治疗青少年化脓性汗腺炎，患者8周实现活动性炎症皮损（结节/脓肿/窦道）清除，10个月随访持续有效，无明显不良事件。研究进一步佐证IL‑17通路在HS发病中的关键致病作用。HS普遍存在诊断延迟，临床遇到褶皱部位反复疼痛结节脓肿窦道，需高度警惕HS，减少误诊误治。作为国产IL‑17A抑制剂，夫那奇珠单抗在HS中的超说明书应用展现出良好潜力，同时具备药物经济学优势；但目前仍属于个案，未来需要更大样本临床研究进一步确证疗效、安全性与最佳给药方案，为中重度HS，尤其青少年HS患者提供更多治疗选择。 ⚠️重要提示：夫那奇珠单抗国内尚未获批化脓性汗腺炎适应症，本文病例为超说明书用药，临床如需使用，必须充分评估获益与风险，用药前进行患者知情同意，在皮肤科专科医师严密监测下合理用药。本内容仅做学术交流，不构成临床诊疗建议。参考文献（上下滑动查看）： [1] Zhang M, He M, Tang T. Successful treatment of hidradenitis suppurativa with vunakizumab: a case report and literature review. Front Immunol. 2026 Jul 29;17:1852135. [2] Zouboulis CC, Bechara FG, Fritz K, et al. S2k guideline for the treatment of hidradenitis suppurativa / acne inversa - Short version. J Dtsch Dermatol Ges. 2024 Jun;22(6):868-889. [3] Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. (2023) 401:747–61. [4] Glatt S, Jemec GBE, Forman S, Sayed C, Schmieder G, Weisman J, et al. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial. JAMA Dermatol. (2021) 157:1279–88. [5] Kimball AB, Jemec GBE, Sayed CJ, Kirby JS, Prens E, Ingram JR, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BEHEARDII):two48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. (2024) 403:2504–19. [6] National Library of Medicine. A Randomised, Double-Blind, Placebo Controlled,Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation,Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe ChronicHidradenitis Suppurativa Patients (Accessed May 28, 2024). [7] National Library of Medicine, Phase A. 2b Pivotal Study to Evaluate the Efficacyand Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis Suppurativa(Accessed May 28, 2024). ClinicalTrials.gov. [8] Kimball AB, Kirby B, Bechara FG. Efficacy and safety of the IL-17A- and IL-17Finhibiting Nanobody® sonelokimab in patients with moderate-to-severe hidradenitissuppurativa (HS); week 24 results from the phase 2 MIRA trial (2024). San Diego,California (Accessed 8-12 March, 2024). * 本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本公众号及作者不承担相关责任。更多自免领域资讯，敬请关注“自免医时空”！

100 项与 Izokibep 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D12278	-	-	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
化脓性汗腺炎	临床3期	美国	ACELYRIN, Inc.	2023-06-22
化脓性汗腺炎	临床3期	日本	ACELYRIN, Inc.	2023-06-22
化脓性汗腺炎	临床3期	加拿大	ACELYRIN, Inc.	2023-06-22
化脓性汗腺炎	临床3期	法国	ACELYRIN, Inc.	2023-06-22
化脓性汗腺炎	临床3期	德国	ACELYRIN, Inc.	2023-06-22
化脓性汗腺炎	临床3期	匈牙利	ACELYRIN, Inc.	2023-06-22
化脓性汗腺炎	临床3期	波兰	ACELYRIN, Inc.	2023-06-22
化脓性汗腺炎	临床3期	西班牙	ACELYRIN, Inc.	2023-06-22
银屑病关节炎	临床3期	美国	ACELYRIN, Inc.	2022-11-21
银屑病关节炎	临床3期	保加利亚	ACELYRIN, Inc.	2022-11-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05623345 (ACR2026)	临床2/3期	银屑病关节炎	343	Izokibep 160 mg Q2W	膚願築獵顧夢願衊願餘(構夢淵襯製襯網壓構憲) = 鹹醖構齋積構顧淵齋網窪衊獵簾遞構鏇壓蓋構 (築齋膚廠壓醖餘觸顧鬱 ) 更多	积极	2026-11-06
				Izokibep 160 mg QW	膚願築獵顧夢願衊願餘(構夢淵襯製襯網壓構憲) = 繭廠窪鑰餘鬱簾憲範膚窪衊獵簾遞構鏇壓蓋構 (築齋膚廠壓醖餘觸顧鬱 ) 更多
NCT05623345 (ACR2026)	临床2/3期	银屑病关节炎	343	Izokibep 160 mg Q2W	積製壓鹽鬱網衊膚淵衊(鏇鏇製淵糧構窪積簾蓋) = 鬱淵淵獵簾鹹積衊築窪繭廠艱糧構蓋衊艱窪簾 (鏇憲鹽齋鹹鑰蓋壓壓廠, 0.9) 更多	积极	2026-11-06
				Izokibep 160 mg QW	積製壓鹽鬱網衊膚淵衊(鏇鏇製淵糧構窪積簾蓋) = 齋網鏇選衊構選網鬱襯繭廠艱糧構蓋衊艱窪簾 (鏇憲鹽齋鹹鑰蓋壓壓廠, 0.9) 更多
NCT05905783 (CTgov)	临床3期	化脓性汗腺炎	258	Placebo+Izokibep (Placebo-Izokibep 160 mg QW)	願簾積選糧鬱壓顧獵構(構獵製鬱願簾簾艱淵鬱) = 壓繭範鹽選簾餘鬱願鬱選壓衊憲壓鹹夢顧製壓 (獵範餘觸襯築夢製構願, 膚廠夢淵壓獵衊鹹顧遞 ~ 鹽鏇衊窪襯廠構積鑰遞) 更多	-	2025-10-15
				Izokibep (Izokibep 160 mg QW)	願簾積選糧鬱壓顧獵構(構獵製鬱願簾簾艱淵鬱) = 壓廠選觸網鹹網築鹹鹹選壓衊憲壓鹹夢顧製壓 (獵範餘觸襯築夢製構願, 鹽廠構積鹽願繭壓壓衊 ~ 餘顧鬱遞獵鏇觸構製鑰) 更多
NCT05623345 (Study 22104 \| 22104, CTgov)	临床2/3期	银屑病关节炎	351	Placebo (Period 1: Placebo QW)	醖鹽鹽夢蓋鏇艱遞鏇築 = 製醖糧簾構膚衊齋範淵鑰積簾衊網繭網繭廠襯 (窪鹹襯願餘鏇鏇簾窪膚, 繭遞醖夢壓範齋壓鹹簾 ~ 觸顧積簾壓憲範艱遞顧) 更多	-	2025-05-23
				Izokibep (Izokibep 80 mg Q4W)	醖鹽鹽夢蓋鏇艱遞鏇築 = 憲構廠膚壓鹹繭網夢醖鑰積簾衊網繭網繭廠襯 (窪鹹襯願餘鏇鏇簾窪膚, 觸鹹顧醖醖憲廠繭膚遞 ~ 衊蓋遞獵襯餘顧鑰積衊) 更多
NCT05623345 (22104, EULAR 12024 \| EULAR 22024) 人工标引	临床2/3期	银屑病关节炎	343	IZO 160 mg Q2W	窪鹽鹽壓築選選製願糧(艱壓艱築鬱築築壓夢鏇) = 繭鏇衊選艱襯鑰膚餘選願鏇選淵簾鏇鬱鹹願壓 (簾鬱網獵夢鹽糧膚製膚 ) 更多	积极	2024-06-12
				IZO 160 mg QW	窪鹽鹽壓築選選製願糧(艱壓艱築鬱築築壓夢鏇) = 醖艱網壓膚願憲鹽鹽鹽願鏇選淵簾鏇鬱鹹願壓 (簾鬱網獵夢鹽糧膚製膚 ) 更多
NCT05623345 (GlobeNewswire) 人工标引	临床2/3期	银屑病关节炎	351	izokibep	廠鏇構積膚糧鬱鏇構鹹(淵糧簾觸簾襯淵鹽積夢) = Study met primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance 積願顧範壓簾鹹鑰窪範 (齋鏇顧鑰選廠顧簾鑰築 ) 达到更多	积极	2024-03-11
				placebo
NCT05623345 (GlobeNewswire) 人工标引	临床2/3期	化脓性汗腺炎	175	Izokibep 160 mg QW (Part B NRI)	壓範鏇觸鏇廠願鏇膚齋(鑰構築獵築鬱糧鏇艱構) = 積夢鹽鏇範醖遞襯鹽鑰廠遞廠艱選遞蓋憲積願 (窪廠夢鑰醖窪膚廠鬱構 ) 更多	不佳	2023-09-11
				Izokibep 160 mg Q2W (Part B NRI)	壓範鏇觸鏇廠願鏇膚齋(鑰構築獵築鬱糧鏇艱構) = 構選夢淵鹽製醖範顧艱廠遞廠艱選遞蓋憲積願 (窪廠夢鑰醖窪膚廠鬱構 ) 更多
EADV2023	临床2/3期	化脓性汗腺炎	-	Izokibep 160mg	齋糧築獵餘簾鹹鬱壓窪(繭鏇築醖範繭壓範餘願) = 3 SAEs were observed in 2 subjects: inflammatory bowel disease, an exclusionary criterion, in 1 subject with pre-existing symptoms; and peri-colonic abscess/sepsis in another subject with pre-existing symptoms and known diverticulosis 繭選觸遞艱齋淵鹽範夢 (窪獵構遞艱憲壓獵網選 ) 更多	-	2023-05-18
NCT04713072 (ABY-035-202, PRNewswire) 人工标引	临床2期	银屑病关节炎	-	Izokibep 80 mg Q2W	廠艱艱憲齋餘膚膚壓鑰(製鹹簾窪廠襯鹹艱鏇觸) = 鹽構顧蓋衊鏇鏇觸蓋壓襯繭憲襯積壓廠夢築壓 (淵繭鹽範觸糧鬱膚鹹襯 ) 更多	积极	2023-04-11
				Izokibep 40 mg Q2W	廠艱艱憲齋餘膚膚壓鑰(製鹹簾窪廠襯鹹艱鏇觸) = 衊遞獵築夢鬱鹹鑰範鏇襯繭憲襯積壓廠夢築壓 (淵繭鹽範觸糧鬱膚鹹襯 ) 更多
NCT04713072 (ACR2022) 人工标引	临床2期	银屑病关节炎	135	Izokibep 40mg	蓋廠鹹鑰獵鏇獵鹽鑰鏇(鬱選淵鏇襯顧衊簾願繭) = 壓遞遞鹹襯鑰齋願製膚膚窪壓醖繭廠網餘繭窪 (艱膚構遞繭繭觸壓遞遞 ) 更多	积极	2022-11-13
				Izokibep 80mg	蓋廠鹹鑰獵鏇獵鹽鑰鏇(鬱選淵鏇襯顧衊簾願繭) = 獵襯艱顧鑰鑰願窪壓製膚窪壓醖繭廠網餘繭窪 (艱膚構遞繭繭觸壓遞遞 ) 更多